Processa Pharmaceuticals to Engage with Industry Leaders
HANOVER, Md. — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a pioneering clinical-stage pharmaceutical company, is excited to announce its participation in the upcoming BIO International Convention. This prestigious event is set to take place from June 16-19, bringing together key players from the biotechnology sector.
Opportunities at the BIO International Convention
The BIO International Convention stands as the largest gathering of biotech enthusiasts worldwide, shaping the future of the industry through networking and collaboration. At this event, Processa's leadership, including CEO Georg Ng and Dr. David Young, President of R&D, will conduct personalized meetings with potential partners and investors. These discussions aim to provide insights into the company's strategic direction and ongoing clinical advancements.
Focus on Next Generation Cancer Therapies
During the convention, Processa will highlight progress related to its Next Generation Cancer (NGC) platform, with a particular emphasis on NGC-Cap, a drug currently undergoing Phase 2 trials for metastatic breast cancer. This innovative approach underscores the company's commitment to developing improved cancer therapies that prioritize patient safety and efficacy.
Strengthening Partnerships for Safer Treatments
CEO Georg Ng expressed enthusiasm about the upcoming convention, stating that it presents a unique platform to showcase the clinical potential of Processa’s NGC therapies. By engaging with partners who share a vision for advancing cancer treatment options, the company aims to foster collaborations that drive innovation in cancer care.
Inviting Conversations with Processa Management
Those interested in connecting with Processa's management team can arrange meetings through the BIO One-on-One Partnering system or by reaching out to Investor Relations. This proactive approach ensures that all stakeholders have the opportunity to learn about the latest developments and partnership possibilities in a personal manner.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals is dedicated to developing cutting-edge cancer treatments. The company's focus is on modifying existing FDA-approved oncology drugs to enhance their safety and effectiveness without altering their fundamental mechanisms. This strategic angle, combined with a robust regulatory pathway, aims to ensure that cancer patients receive more tolerable and effective therapies. By integrating their oncology pipeline with established drug molecules, Processa works tirelessly to provide superior options for patients facing life-threatening conditions.
Frequently Asked Questions
What is the BIO International Convention?
The BIO International Convention is a significant annual event that gathers leaders from the biotechnology industry for networking, collaboration, and discussions around innovation in life sciences.
How can I meet with Processa Pharmaceuticals at the BIO Convention?
Meetings can be scheduled through the BIO One-on-One Partnering system or by contacting Investor Relations directly.
What specific therapeutic advancements will Processa highlight?
Processa will showcase its Next Generation Cancer therapies, particularly focusing on its lead asset, NGC-Cap, which is in Phase 2 trials for metastatic breast cancer.
Who are the key executives attending the event?
The management team includes Georg Ng, CEO, and Dr. David Young, President of R&D, who will be leading discussions with stakeholders.
What is Processa's mission?
Processa Pharmaceuticals aims to enhance cancer treatment options with therapies that not only maintain efficacy but also improve patient safety and tolerability.
